Skin detachment and regrowth in toxic epidermal necrolysis

Case Reports in Dermatology

Volumn 2, Issue 1, 2010, Pages 60-64

  Feldmeyer, Laurence ^a   Harr, Thomas ^a   Cozzio, Antonio ^a   French, Lars E ^a   Navarini, Alexander A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Lyell; Reepithelialization; Toxic epidermal necrolysis

Indexed keywords

ACETYLSALICYLIC ACID; CEFUROXIME; DIPYRONE; HYDROCORTISONE; IMMUNOGLOBULIN; PARACETAMOL; SILVER;

ADOLESCENT; ALOPECIA; ARTICLE; BLEEDING; BLISTER; CASE REPORT; DRY EYE; EMULSION; EPIDERMIS; EPITHELIZATION; EYE INJURY; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYDRATION; HYDROPHILICITY; HYPOPIGMENTATION; LYMPHOCYTE TRANSFORMATION TEST; MOUTH LESION; NUTRITIONAL SUPPORT; OINTMENT; ORAL MUCOSAL DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHINITIS; SKIN BIOPSY; SKIN DEFECT; SKIN EXFOLIATION; SKIN SURFACE; SKIN ULCER; TISSUE REGENERATION; TOPICAL TREATMENT; TOXIC EPIDERMAL NECROLYSIS; WOUND CARE; WOUND DRESSING;

EID: 77958539662     PISSN: None     EISSN: 16626567     Source Type: Journal    
DOI: 10.1159/000313866     Document Type: Article

References (17)

1. Lyell A: Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-361.
2. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-493.
3. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE: Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32.
4. French LE, Trent JT, Kerdel FA: Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 2006;6:543-549.
5. Abood GJ, Nickoloff BJ, Gamelli RL: Treatment strategies in toxic epidermal necrolysis syndrome: where are we ató J Burn Care Res 2008;29:269-276.
6. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-1589.
7. Trent J, Ma F, Kerdel F, Fien S, French LE, Romanelli P, Kirsner RS: Dose of intravenous immunoglobulin and patient survival in SJS and toxic epidermal necrolysis. Exp Rev Dermatol 2007;2:299-303.
8. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. European Dermatology Forum, 2009.
9. Trent JT, Kirsner RS, Romanelli P, Kerdel FA: Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience. Arch Dermatol 2003;139:39-43.
10. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L: High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003;83:430-432.
11. Al-Mutairi N, Arun J, Osama NE, Amr Z, Mazen AS, Ibtesam el-A, Nazeha el-B: Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 2004;43:847-851.
12. Shortt R, Gomez M, Mittman N, Cartotto R: Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2004;25:246-255.
13. Tan AW, Thong BY, Yip LW, Chng HH, Ng SK: High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol 2005;32:1-6.
14. Stella M, Clemente A, Bollero D, Risso D, Dalmasso P: Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 2007;33:452-459.
15. Bachot N, Revuz J, Roujeau JC: Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-36.
16. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL: Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 2004;25:81-88.
17. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M: Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008;58:33-40.